Tafamidis treatment of transthyretin mediated amyloidosis (TTR) approved by FDA
May 16, 2019
Mazen Hanna, MD, Co-Director of the Cleveland Clinic's Amyloidosis Center talks about the FDA's recent approval of the drug Tafamidis for the treatment of ATTR Amyloidosis(also known as Amyloid Transthyretin Amyloidosis), the research behind it, what this medication does, and what this means for patients.
Subscribe: Apple Podcasts | Spotify
Tafamidis treatment of transthyretin mediated amyloidosis (TTR) approved by FDA
Cardiac Consult
A Cleveland Clinic podcast exploring heart, vascular and thoracic topics of interest to healthcare providers: medical and surgical treatments, diagnostic testing, medical conditions, and research, technology and practice issues.
